Targeting mucosal-associated invariant T cells using riboflavin metabolism derived TCR ligands for innate immunotherapy of liver cancer
Rattachement africain : de, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Mucosal-associated invariant T (MAIT) cells are an abundant T cell subset in the human liver and they play a crucial role in the regulation of immunity and inflammation. MAIT cells can be activated and expanded using riboflavin metabolism-derived T cell receptor (TCR) agonists. The aim of this work was to resolve the underlying mechanisms of MAIT-mediated anti-tumor immunity in human and mouse. Methods: Ex vivo co-culture systems and cytotoxicity assays were used to investigate the effect of riboflavin-derived TCR-ligands on human circulating and hepatic MAIT cells. Syngeneic mouse models of orthotopic primary liver cancer and liver metastases were used to study anti-tumor activity of MAIT cells. A series of pharmacological depletion experiments were used to identify additional effector immune cells and humoral factors that mediate this effect in vivo. Single-cell RNA sequencing and high-dimensional flow cytometry provided crucial clues to underlying mechanisms. Results: We show that MAIT cells are potent mediators of this anti-tumor activity across various models of liver cancer in vivo and in vitro when activated by distinct MAIT TCR-ligands. Sequencing and flow cytometry identified co-stimulatory effector molecules as critical components required for MAIT-induced tumor suppression. Additional pharmacological depletion experiments and genomic conditional knockout mouse strains helped to identify additional effector cells. Conclusion: MAIT cells play an important role in tumor immunology and represent an attractive new target for immunotherapy. Finely tuned, context-dependent mechanisms determine MAIT cell function in vivo and in vitro. Publication History Article published online: 04 September 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Targeting mucosal-associated invariant T cells using riboflavin metabolism derived TCR ligands for innate immunotherapy of liver cancer
- Date Crossref
- 01/09/2025
- Éditeur
- Georg Thieme Verlag KG
- Type
- proceedings-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.